BioCentury | Sep 7, 2015
Financial News

Xerion completes venture financing

Xerion Healthcare Ltd. , Thame, U.K. Business: Cancer Date completed: 2015-08-24 Type: Venture financing Raised: L1.5 million ($2.4 million) Investors: New Wave Ventures; Parkwalk Advisors WIR Staff cancer...
BioCentury | Apr 23, 2012
Strategy

Cracking the code

...three in 2011. Chiome's European consultant is Fritz Rudert, formerly head of business development at Xerion...
...Pink:MPSYF), Martinsried, Germany OncoMed Pharmaceuticals Inc. , Redwood City, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Xerion...
BioCentury | Jan 10, 2005
Company News

Three German insolvencies

...Infectious disease company Axxima and antibody play Xerion filed for insolvency. Each company is now being...
...1997. TVM was lead investor in a $12.2 million series D round in June 2004. Xerion...
...in 1998. Heidelberg Innovation led a $11.8 million series C round led in October 2002. Xerion...
BioCentury | Aug 30, 2004
Company News

Xerion management update

Xerion Pharmaceuticals AG , Munich, Germany Business: Antibodies, Cancer Departed: Leodevico Ilag as chief technology officer to become CSO at Cryptome Pharmaceuticals Ltd. WIR Staff...
BioCentury | Jun 14, 2004
Company News

Stemline, Xerion deal

...Xerion will jointly identify protein targets expressed on cancer stem cells. The companies will use Xerion's...
...will have the option to co-develop any targets. Stemline Therapeutics Inc. , New York, N.Y. Xerion Pharmaceuticals AG...
BioCentury | Jun 9, 2004
Company News

Stemline, Xerion target ID deal

...Stemline (New York, N.Y.) and Xerion (Munich, Germany) will jointly identify protein targets expressed on cancer...
...use Stemline's StemScreen stem cell platform to identify druggable targets on cancer stem cells and Xerion's...
BioCentury | Jan 26, 2004
Company News

Medarex, Xerion Pharmaceuticals GmbH deal

...MEDX and Xerion partnered to develop human antibodies. Under the deal, Xerion will use its Xstream...
...equally the costs and responsibilities of product development and commercialization. Medarex Inc. (MEDX), Princeton, N.J. Xerion...
BioCentury | Jan 20, 2004
Company News

MEDX, Xerion antibody deal

...Medarex (MEDX) and Xerion (Munich, Germany) partnered to develop human antibodies. Under the deal, Xerion will...
BioCentury | Oct 27, 2003
Strategy

Partnering with mid-sized pharma

...Micromet 5/01 Target identification to develop lung cancer targets Xerion 10/01 Target validation based on Xerion's...
BioCentury | Sep 8, 2003
Company News

Cambridge Antibody, Xerion Pharmaceuticals GmbH deal

...CAT and Xerion expanded a 2001 deal under which CAT licensed to Xerion its antibody phage...
...discovery, target validation and functional proteomics (see BioCentury, June 11, 2001). As expanded, CAT granted Xerion...
...CAT's antibody phage display libraries. The antibodies are directed against disease-associated protein targets characterized using Xerion's...
Items per page:
1 - 10 of 39
BioCentury | Sep 7, 2015
Financial News

Xerion completes venture financing

Xerion Healthcare Ltd. , Thame, U.K. Business: Cancer Date completed: 2015-08-24 Type: Venture financing Raised: L1.5 million ($2.4 million) Investors: New Wave Ventures; Parkwalk Advisors WIR Staff cancer...
BioCentury | Apr 23, 2012
Strategy

Cracking the code

...three in 2011. Chiome's European consultant is Fritz Rudert, formerly head of business development at Xerion...
...Pink:MPSYF), Martinsried, Germany OncoMed Pharmaceuticals Inc. , Redwood City, Calif. Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Xerion...
BioCentury | Jan 10, 2005
Company News

Three German insolvencies

...Infectious disease company Axxima and antibody play Xerion filed for insolvency. Each company is now being...
...1997. TVM was lead investor in a $12.2 million series D round in June 2004. Xerion...
...in 1998. Heidelberg Innovation led a $11.8 million series C round led in October 2002. Xerion...
BioCentury | Aug 30, 2004
Company News

Xerion management update

Xerion Pharmaceuticals AG , Munich, Germany Business: Antibodies, Cancer Departed: Leodevico Ilag as chief technology officer to become CSO at Cryptome Pharmaceuticals Ltd. WIR Staff...
BioCentury | Jun 14, 2004
Company News

Stemline, Xerion deal

...Xerion will jointly identify protein targets expressed on cancer stem cells. The companies will use Xerion's...
...will have the option to co-develop any targets. Stemline Therapeutics Inc. , New York, N.Y. Xerion Pharmaceuticals AG...
BioCentury | Jun 9, 2004
Company News

Stemline, Xerion target ID deal

...Stemline (New York, N.Y.) and Xerion (Munich, Germany) will jointly identify protein targets expressed on cancer...
...use Stemline's StemScreen stem cell platform to identify druggable targets on cancer stem cells and Xerion's...
BioCentury | Jan 26, 2004
Company News

Medarex, Xerion Pharmaceuticals GmbH deal

...MEDX and Xerion partnered to develop human antibodies. Under the deal, Xerion will use its Xstream...
...equally the costs and responsibilities of product development and commercialization. Medarex Inc. (MEDX), Princeton, N.J. Xerion...
BioCentury | Jan 20, 2004
Company News

MEDX, Xerion antibody deal

...Medarex (MEDX) and Xerion (Munich, Germany) partnered to develop human antibodies. Under the deal, Xerion will...
BioCentury | Oct 27, 2003
Strategy

Partnering with mid-sized pharma

...Micromet 5/01 Target identification to develop lung cancer targets Xerion 10/01 Target validation based on Xerion's...
BioCentury | Sep 8, 2003
Company News

Cambridge Antibody, Xerion Pharmaceuticals GmbH deal

...CAT and Xerion expanded a 2001 deal under which CAT licensed to Xerion its antibody phage...
...discovery, target validation and functional proteomics (see BioCentury, June 11, 2001). As expanded, CAT granted Xerion...
...CAT's antibody phage display libraries. The antibodies are directed against disease-associated protein targets characterized using Xerion's...
Items per page:
1 - 10 of 39